Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio lessened its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 25.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,735 shares of the company’s stock after selling 8,231 shares during the quarter. Public Employees Retirement System of Ohio owned approximately 0.08% of Medpace worth $8,257,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. Signaturefd LLC boosted its position in Medpace by 4.9% during the second quarter. Signaturefd LLC now owns 559 shares of the company’s stock worth $230,000 after acquiring an additional 26 shares during the last quarter. Wealth Alliance boosted its holdings in shares of Medpace by 2.9% during the second quarter. Wealth Alliance now owns 970 shares of the company’s stock worth $399,000 after purchasing an additional 27 shares during the last quarter. Centaurus Financial Inc. grew its position in shares of Medpace by 2.0% in the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after purchasing an additional 29 shares during the period. Commonwealth Equity Services LLC increased its stake in Medpace by 0.7% in the second quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock valued at $1,787,000 after purchasing an additional 32 shares during the last quarter. Finally, Lindenwold Advisors INC lifted its position in Medpace by 1.6% during the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock worth $676,000 after buying an additional 32 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on MEDP shares. Redburn Atlantic started coverage on Medpace in a report on Monday, October 14th. They issued a “buy” rating and a $404.00 price target for the company. TD Cowen dropped their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. StockNews.com lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Robert W. Baird increased their target price on Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a research report on Monday, November 25th. Finally, Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $380.56.

Medpace Stock Up 1.7 %

NASDAQ MEDP opened at $347.43 on Friday. Medpace Holdings, Inc. has a fifty-two week low of $277.72 and a fifty-two week high of $459.77. The business has a 50 day moving average price of $339.14 and a two-hundred day moving average price of $368.27. The stock has a market cap of $10.80 billion, a PE ratio of 30.42, a P/E/G ratio of 1.94 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. The firm had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.22 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.